New drug flonoltinib maleate tested for safety in healthy people
NCT ID NCT06387966
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tested the safety and how the body processes flonoltinib maleate tablets in 40 healthy adults in China. Participants received a single oral dose of the drug or a placebo, with doses increasing across groups. The study focused on side effects and drug levels in blood and urine, not on treating any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Flonoltinib maleate tablets
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEATHLY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chengdu Xinhua Hospital
Chengdu, Sichuan, 610000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.